Analyst Ratings For Corium International Inc (NASDAQ:CORI)
Today, Corium International Inc (NASDAQ:CORI) stock was downgraded by Needham & Company LLC from Buy to Hold.
There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Corium International Inc (NASDAQ:CORI) is Buy with a consensus target price of $12.75 per share, a potential 0.39% upside.
Some recent analyst ratings include
- 10/15/2018-Corium International Inc (NASDAQ:CORI) gets downgraded to Hold by Needham & Company LLC
- 10/15/2018-Corium International Inc (NASDAQ:CORI) gets downgraded to Neutral by HC Wainwright with a price target of $13.00
- 8/10/2018-Corium International Inc (NASDAQ:CORI) had its Buy rating reiterated by Cantor Fitzgerald with a $14.00 price target
- 4/18/2017-Corium International Inc (NASDAQ:CORI) had its Outperform ➝ Outperform rating reiterated by FBR & Co with a $13.00 price target
- 1/4/2017-Corium International Inc (NASDAQ:CORI) had its Buy rating reiterated by Leerink Swann
- On 8/17/2018 Joseph J. Sarret, Insider, sold 3,565 with an average share price of $9.01 per share and the total transaction amounting to $32,120.65.
- On 8/17/2018 Parminder Singh, VP, sold 3,133 with an average share price of $9.01 per share and the total transaction amounting to $28,228.33.
- On 8/17/2018 Peter D Staple, CEO, sold 76,341 with an average share price of $8.81 per share and the total transaction amounting to $672,564.21.
- On 8/17/2018 Robert S. Breuil, CFO, sold 972 with an average share price of $9.01 per share and the total transaction amounting to $8,757.72.
- On 8/17/2018 Timothy D. Sweemer, CAO, sold 346 with an average share price of $9.01 per share and the total transaction amounting to $3,117.46.
- On 8/15/2018 Robert Thomas, Director, sold 35,608 with an average share price of $8.86 per share and the total transaction amounting to $315,486.88.
- On 1/18/2018 Life Sciences Maste Perceptive, Major Shareholder, bought 510,000 with an average share price of $12.54 per share and the total transaction amounting to $6,395,400.00.
About Corium International Inc (NASDAQ:CORI)
Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Recent Trading Activity for Corium International Inc (NASDAQ:CORI)
Shares of Corium International Inc closed the previous trading session at 12,70 up +4,39 52,83 % with 12.79 shares trading hands.